United States ex rel. Banigan v. Organon USA Inc.
883 F. Supp. 2d 277
D. Mass.2012Background
- Relators Banigan and Templin filed a qui tam action under the FCA on behalf of the United States, 27 states, D.C., and Chicago, naming Organon entities, Omnicare, and PharMerica as defendants; Akzo Nobel N.V. appears in corporate lineage but is not liable in this posture.
- Relators’ TAC asserts kickback schemes to induce LTCPs to prescribe Remeron (Remeron Tablet and Remeron SolTab), together with related pricing and off-label marketing claims against Organon.
- LTCPs (Omnicare and PharMerica) allegedly received or solicited kickbacks in exchange for promoting Remeron and for therapeutic interchange and market share; Organon allegedly used incentives and data-sharing agreements.
- Pricing claims allege that Organon concealed best price, manipulated AMP, and evaded rebates in Medicaid rebates under the CMS reporting regime, thus reducing liability.
- Off-label marketing claims contend Organon promoted off-label uses of Remeron to maximize reimbursement in Medicaid, including uses not medically accepted, and paid physician kickbacks.
- The court analyzes jurisdictional bars (first-to-file and public disclosure), then addresses Rule 9(b) pleading and Rule 12(b)(6) challenges, and finally resolves state/local claims and remaining counts.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| First-to-file bar applicability | Relators argue AmeriSource bars apply to PharMerica and Organon. | PharMerica and Organon contend prior AmeriSource case does not bar due to non-identical drug names/details. | AmeriSource bars all federal claims against PharMerica and certain Organon claims. |
| Public disclosure bar applicability | Relators contend disclosures in AmeriSource and Texas documents publicize the fraud. | Defendants argue broader or non-specific disclosures may bar claims. | AmeriSource public disclosures bar the federal kickback and pricing claims against PharMerica and Organon. |
| Off-label marketing claims vs. Medicaid reimbursement | Organon’s off-label Remeron promotions were actionable as false/fraudulent under FCA. | Medicaid may reimburse off-label/non-compendium uses; not automatically false. | Off-label claims fail under Rule 12(b)(6) due to lack of proven non-reimbursable/off-label basis. |
| Omnicare kickback claims viability | Kickbacks alleged against Omnicare should be actionable under FCA. | Safe harbors and lack of particularity may shield Omnicare. | Direct kickback claims survive under §3729(a)(1); collateral kickbacks insufficiently pleaded; §3729(a)(2)/(a)(3) survive. |
Key Cases Cited
- U.S. ex rel. Rost v. Pfizer, Inc., 507 F.3d 720 (3d Cir. 2007) (threshold jurisdictional questions in FCA cases)
- United States ex rel. Duxbury v. Ortho Biotech Products, L.P., 579 F.3d 13 (1st Cir. 2009) (first-to-file standard and essential facts bar)
- U.S. ex rel. St. John LaCorte v. AmeriSource Bergen Corp., (unofficial; see text) (—) (public disclosures bar analysis in kickback context)
- U.S. ex rel. Lisitza v. Omnicare, Inc., 765 F. Supp. 2d 112 (D. Mass. 2011) (first-file/public disclosure considerations in Omnicare-related claims)
- Allison Engine Co., Inc. v. U.S. ex rel. Sanders, 553 U.S. 662 (U.S. 2008) (imposes specific intent requirement for 3729(a)(2)/(a)(3) claims)
- Gagne v. City of Worcester, 565 F.3d 40 (1st Cir. 2009) (pleading particularity standard under FCA § 3729)
- Bahler Medical v. Feingold, 619 F.3d 110 (7th Cir. 2010) (public disclosures analysis in FCA bar)